Adaptive β-cell proliferation increases early in high-fat feeding in mice, concurrent with metabolic changes, with induction of islet cyclin D2 expression
Open accessAbstract
Type 2 diabetes (T2D) is caused by relative insulin deficiency, due in part to reduced β-cell mass (11, 62). Therapies aimed at expanding β-cell mass may be useful to treat T2D (14). Although feeding rodents a high-fat diet (HFD) for an extended period (3-6 mo) increases β-cell mass by inducing β-cell proliferation (16, 20, 53, 54), evidence suggests that adult human β-cells may not meaningfully proliferate in response to obesity. The timing and identity of the earliest initiators of the rodent compensatory growth response, possible therapeutic targets to drive proliferation in refractory human β-cells, are not known. To develop a model to identify early drivers of β-cell proliferation, we studied mice during the first week of HFD exposure, determining the onset of proliferation in the context of diet-related physiological changes. Within the first week of HFD, mice consumed more kilocalories, gained weight and fat mass, and developed hyperglycemia, hyperinsulinemia, and glucose intolerance due to impaired insulin secretion. The β-cell proliferative response also began within the first week of HFD feeding. Intriguingly, β-cell proliferation increased before insulin resistance was detected. Cyclin D2 protein expression was increased in islets by day 7, suggesting it may be an early effector driving compensatory β-cell proliferation in mice. This study defines the time frame and physiology to identify novel upstream regulatory signals driving mouse β-cell mass expansion, in order to explore their efficacy, or reasons for inefficacy, in initiating human β-cell proliferation.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Muscle-released ELVs contribute to adaptations in beta cell mass occurring during insulin-resistance associated with obesity, at least in mice.
“it would suggest that muscle-released ELVs would contribute to adaptations in beta cell mass occurring during insulin-resistance associated with obesity, at least in mice”
From Skeletal Muscle-Released Extracellular Vesicles: State of the Art (2019) · cites this paper as Stamateris et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 64 · Cited by 138
- Authors
- Stamateris, R. E., Sharma, R. B., Hollern, D. A., & Alonso, L. C.
- Affiliations
- University of Massachusetts Chan Medical School (US)
- Corresponding author
- Alonso, Laura C.
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2013-07-01
- Volume
- 305
- Issue
- 1
- Pages
- E149-E159
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- PMC
- PMC3725565
- OpenAlex
- W2059379685
- Cited by
- 138
- References
- 64
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 6 · 2023: 8 · 2022: 14 · 2021: 8 · 2020: 13 · 2019: 15 · 2018: 9 · 2017: 14 · 2016: 16 · 2015: 5 · 2014: 12 · 2013: 1
- FWCI
- 11.18
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-02-08)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Physiology-Endocrinology and Metabolism (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK095140)
- Topics
- Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- beta-cell proliferation, high-fat diet, cyclin D2, type 2 diabetes, impaired glucose tolerance, hyperinsulinemia, hyperglycemia, islets, obesity, insulin secretion
- MeSH terms
- Adaptation, Physiological, Animals, Blood Glucose, Energy Intake, Dietary Fats, Hyperglycemia, Hyperinsulinism, Insulin, Insulin Resistance, Male, Mice, Inbred C57BL, Weight Gain, Glucose Intolerance, Cell Proliferation, Insulin-Secreting Cells, Mice, Cyclin D2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review